Early immunomodulator use cuts risk in Crohn’s

Use of thiopurines or methotrexate within three years of diagnosis reduces the need for both initial and recurrent surgery in Crohn’s disease, a large Australian study finds.

Surgical rates five years on from diagnosis decreased from 38% in those who did not benefit from early immunomodulator (IM) therapy to 23% in those who did, showed data from over 1,000 consecutive patients diagnosed from 1970 to 2009.

Early IM use